Combination therapy study for advanced kidney cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests new drug combinations for people with advanced kidney cancer whose disease returned after a prior immunotherapy. It's designed to find better treatment options for those who have not received other treatments for advanced disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of kidney cancer called clear cell renal cell carcinoma that has spread or cannot be removed with surgery.
- You have not had any other cancer treatment besides a type of immunotherapy called a PD-(L)1 inhibitor given after surgery.
- Your cancer returned while on that immunotherapy or within 2 years of finishing it.
- You can swallow pills.
- You must provide a tissue sample from a previous biopsy or have a new biopsy for testing.
- Your blood pressure is well-controlled, with or without medication.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two new drugs, belzutifan and zanzalintinib, for people with advanced kidney cancer that returned after or within 2 years of finishing an immunotherapy treatment after surgery. You cannot have received any other cancer treatments besides that immunotherapy.
This trial tests an experimental drug (HC-7366) combined with an approved targeted therapy (belzutifan) for people with advanced kidney cancer. It aims to see if the combination is safe and works better than either drug alone.
This study tests a new combination of medications (casdatifan and zimberelimab) given before surgery to remove kidney tumors in people with clear cell renal cell carcinoma (ccRCC). The goal is to see if this approach can help shrink the tumor or improve outcomes.
This trial tests a combination of three medicines—pembrolizumab (a drug that helps your immune system fight cancer), belzutifan, and lenvatinib (drugs that slow tumor growth)—in patients with early-stage kidney cancer who are candidates for surgery. The goal is to see if this combination can improve outcomes before or alongside surgery.
This trial tests a new drug called zanzalintinib for people with advanced clear cell kidney cancer that has spread to the bones (at least 3 spots). The study wants to see if this drug can help slow down or shrink the cancer. It's for patients who have already had some prior treatments.
This study tests two new drugs, belzutifan and zanzalintinib, for people with advanced kidney cancer that has not responded well to other treatments. The goal is to see if the combination slows down cancer growth.
Hear when a new Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.